...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Integrative cancer therapies >Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
【24h】

Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.

机译：中药草药治疗可能对铂类化学疗法或联合靶向治疗和化学疗法治疗的IV期肺腺癌患者的预后产生相关影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Targeted therapy (TT), chemotherapy, and traditional Chinese medicine herbal treatment (TCM) can improve the prognosis of advanced pulmonary adenocarcinoma patients. Their independent prognostic value is unknown. OBJECTIVE: To study whether TCM improves survival in stage IV pulmonary adenocarcinoma patients with platinum-based chemotherapy (PBT), or combined PBT and second-line TT. METHODS: Retrospective analysis of 133 fully ambulant clinical outpatients treated with PBT alone or PBT with/without second-line TT, with/without TCM. Univariate (Kaplan-Meier) and multivariable (Cox model) survival analysis were performed, using disease-specific mortality as an endpoint. RESULTS: Gender (P = .002), TT (P < .0001), and TCM (P < .0001) had univariate prognostic value but not age, radiotherapy, or TCM syndrome differentiation (P > .10). TCM herbal treatment (P < .0001) and TT (P = .03) had multivariable independent prognostic value. TCM-treated patients (n = 103, PBT+TT+TCM+ = 62; PBT+TT-TCM+ =41) had 88% 1-year overall survival rate with median survival time (MST) of 27 months, contrasting 27% 1-year overall survival and MST of 5.0 months for non-TCM-treated (n = 30) patients. Patients with chemotherapy/TT/TCM (PBT+TT+TCM+, n = 62), TCM without TT (PBT+TT-TCM+, n = 41), or chemotherapy only (PBT+TT-TCM-, n = 30), had 1-year survival rates of 94%, 78%, and 27% respectively; for these 3 groups, respectively, MST was not reached (MST of 30.9 months), 22.6, and 5.0 months (P < .0001). CONCLUSIONS: TCM herbal treatment may improve survival of stage IV pulmonary adenocarcinoma patients treated with chemotherapy without or with second-line TT. This warrants formal phase 1 and 2 trials and ultimately properly designed prospective clinical validation trials with adequate methodology developed for data collection.
机译：背景：靶向治疗（TT），化学疗法和中药草药治疗（TCM）可以改善晚期肺腺癌患者的预后。它们的独立预后价值未知。目的：研究中药能否提高铂类化学疗法（PBT）或PBT与二线TT联合治疗IV期肺腺癌患者的生存率。方法：回顾性分析133名接受单独PBT或PBT合并/不合并二线TT，合并/不合并TCM的完全门诊的门诊患者。以疾病特异性死亡率为终点，进行单因素（Kaplan-Meier）和多因素（Cox模型）生存分析。结果：性别（P = .002），TT（P <.0001）和TCM（P <.0001）具有单因素预后价值，但没有年龄，放疗或中医辨证分型（P> .10）。中医草药治疗（P <.0001）和TT（P = .03）具有多变量独立预后价值。中医治疗的患者（n = 103，PBT + TT + TCM + = 62; PBT + TT-TCM + = 41）的1年总生存率为88％，中位生存时间（MST）为27个月，而27％1非TCM治疗（n = 30）患者的一年总生存和5.0个月的MST。患有化疗/ TT / TCM（PBT + TT + TCM +，n = 62），无TT的TCM（PBT + TT-TCM +，n = 41）或仅接受化疗（PBT + TT-TCM-，n = 30）的患者， 1年生存率分别为94％，78％和27％;对于这3组，分别未达到MST（MST为30.9个月），22.6和5.0个月（P <.0001）。结论：中药草药治疗可以提高IV期肺腺癌患者的生存率，而无或不行二线TT化疗均可以治愈。这保证了正式的1期和2期试验以及最终设计合理的前瞻性临床验证试验，以及为数据收集开发的适当方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号